Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Kymera Therapeutics has raised $602.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2025.
Kymera Therapeutics's investors include Wellington Management, BlackRock, Bessemer Venture Partners, Janus Henderson Investors, Redmile Group.
Kymera Therapeutics is headquartered in Cambridge, United States.
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Kymera Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kymera Therapeutics — Funding & Investors." VCBacked, December 10, 2025, https://www.vcbacked.co/company/kymera-therapeutics. Accessed August 15, 2026.
VCBacked. (2025). Kymera Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/kymera-therapeutics
{{cite web |title=Kymera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kymera-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated